Bristol-Myers Squibb to acquire Mirati in deal worth up to $5.8B

Yahoo Finance Video
25,705 次觀看・1 年前

Bristol-Myers Squibb (BMY) has agreed to buy cancer drugmaker Mirati Therapeutics (MRTX) for up to $5.8 billion. The deal will diversify Bristol-Myers Squibb's drugs pipeline and add new treatments to its portfolio as sales of some of its older products compete with generics. Yahoo Finance Live hosts Seana Smith and Brad Smith break down the details of the deal.

For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.